Vanda Pharmaceuticals Inc.
VNDA
Positions held
Your positionsVNDA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $273.90M | Enterprise value | $126.70M | Trailing P/E | — | Forward P/E | 22.65 |
| PEG | 2.23 | Price / book | 0.97 | Beta | 0.69 | Dividend yield | 0.00% |
| Revenue growth | -3.9% | Earnings growth | — | Gross margin | 93.7% | Operating margin | -126.3% |
| Profit margin | -127.4% | ROE | -77.8% | ROA | -22.4% | Debt / equity | 0.10 |
| Current ratio | 1.61 | Free cash flow | -$86.72M | Analyst recommendation | strong_buy | Mean target | $11.75 |
| 52w high | $9.94 | 52w low | $4.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $50.5M | $51.7M | $57.2M | $56.3M | $52.6M |
| Op margin | -126.3% | -97.1% | -70.5% | -55.6% | -73.2% |
| Net income | -$62.5M | -$48.6M | -$141M | -$22.6M | -$27.2M |
| Gross margin | 93.0% | 93.9% | 93.3% | 94.7% | 94.8% |
| Gross profit | $47.0M | $48.6M | $53.4M | $53.3M | $49.9M |
| Operating income | -$63.8M | -$50.2M | -$40.4M | -$31.3M | -$38.5M |
- Revenue -2% vs prior quarter ($51M vs $52M).
- Gross margin 93% (was 93.9% prior quarter).
- Operating margin compressed to -126.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $216M | $199M | $193M | $254M |
| Op margin | -70.0% | -20.5% | -7.2% | 2.5% |
| Net income | -$220M | -$18.9M | $2.5M | $6.3M |
| Gross margin | 94.0% | 94.3% | 92.3% | 90.5% |
| Gross profit | $203M | $187M | $178M | $230M |
| Operating income | -$151M | -$40.7M | -$14.0M | $6.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
2026-09-30 · VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
2026-09-30 · Vanda's Late-Stage Trial of Sleep Disorder Drug Meets Primary Goal
2026-09-30 · Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
2026-09-02 · Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
2026-08-31 · BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
2026-08-24 · Vanda Pharmaceuticals' Skin Disease Drug Gets EU Orphan Drug Designation
2026-08-22 · NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
2026-08-12 · Vanda (VNDA) Q2 2026 Earnings Call Transcript
2026-08-11 · 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Price (daily)
Full chart · RSI · MACD · patterns